These two Food and Drug Administration-approved drugs for cancer treatment may hold the key to reversing Alzheimer's disease ...

Alector’s 71% drop prompts a fresh look at its valuation, financials, and pipeline to gauge recovery prospects amid lingering ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

TOKYO, July 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 24th ...

The Approved Product, together with the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops collectively, collectively provide more high-quality treatment options for patients ...

The combination of a recently approved blood test for detection of Alzheimer’s disease combined with two medications that slow progression of the disease is drastically improving outcomes for patients ...

UCSF researchers found the cancer drugs letrozole and irinotecan may reverse Alzheimer's effects, reducing tau protein clumps ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...